This ADC targets HER2, not topoisomerase I. After HER2 binding and internalization, the DXd payload is released and inhibits topoisomerase I to cause DNA damage and apoptosis (with ADCC and bystander effects). Thus, killing is directed by HER2 expression, not by expression of topoisomerase I itself.